Marina Biotech, Inc. to Present at The 10th Annual BIO Investor Forum

BOTHELL, WA--(Marketwire - Oct 19, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it will present at The 10^th Annual BIO Investor Forum on Wednesday, October 26, 2011, at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time) at the Palace Hotel in San Francisco. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview and business update.

A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at http://www.marinabio.com. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.